Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Update

Tenax Therapeutics, Inc. (NASDAQ:TENX) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 35,200 shares, a decline of 28.2% from the March 31st total of 49,000 shares. Approximately 1.9% of the shares of the company are short sold. Based on an average trading volume of 339,800 shares, the short-interest ratio is presently 0.1 days.

Tenax Therapeutics Price Performance

NASDAQ:TENX traded up $0.19 during midday trading on Monday, hitting $3.67. 102,141 shares of the stock were exchanged, compared to its average volume of 275,365. The business has a 50-day moving average price of $3.94 and a two-hundred day moving average price of $13.86. Tenax Therapeutics has a one year low of $3.47 and a one year high of $61.20.

Analyst Ratings Changes

A number of analysts recently weighed in on TENX shares. StockNews.com initiated coverage on shares of Tenax Therapeutics in a report on Wednesday, January 10th. They issued a “sell” rating on the stock. Roth Mkm restated a “buy” rating on shares of Tenax Therapeutics in a research report on Tuesday, February 20th.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.